CNVY · Convey Health Solutions Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q3 '19 | Q2 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $89.78M | $96.71M | - | $82.41M | $61.56M | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $24.09M | $23.21M | - | $21.30M | $29.59M | - | - | - | - | - |
| Total Operating Expenses | $98.17M | $79.11M | - | $74.31M | $82.15M | - | - | - | - | - |
| D&A | $9.01M | $7.37M | - | $6.92M | $6.95M | - | - | - | - | - |
| Operating Income | ($8.38M) | $3.53M | - | $2.44M | ($2.92M) | - | - | - | - | - |
| Interest Expense | $4.19M | $3.72M | - | $4.56M | $6.39M | - | - | - | - | - |
| Income Tax | ($2.68M) | ($676.0K) | - | $1.13M | ($1.54M) | - | - | - | - | - |
| Net Income | ($9.89M) | ($1.15M) | - | $3.69M | ($13.14M) | - | - | - | - | - |
| EPS - Basic | ($0.14) | ($0.02) | - | $0.05 | ($0.21) | - | - | - | - | - |
| EPS - Diluted | ($0.14) | ($0.02) | - | ($0.03) | ($0.21) | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q3 '19 | Q2 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.71M | $20.87M | $38.81M | $41.23M | $29.09M | $45.37M | $15.97M | $21.46M | $0 | $18.26M |
| Accounts Receivable | $71.56M | $72.71M | $62.81M | $46.80M | $44.56M | - | - | - | - | - |
| Inventory | $38.57M | $36.41M | $14.06M | $13.86M | $11.09M | - | - | - | - | - |
| Accounts Payable | $8.22M | $11.16M | $13.87M | $11.86M | $8.61M | - | - | - | - | - |
| Current Assets | $141.17M | $140.79M | $132.25M | $113.55M | $96.34M | - | - | - | - | - |
| Total Assets | $911.71M | $916.53M | $829.90M | $814.36M | $843.07M | - | - | - | - | - |
| Current Liabilities | $64.06M | $57.57M | $70.40M | $58.99M | $97.79M | - | - | - | - | - |
| Long-term Debt | $264.59M | $264.48M | $189.64M | $189.48M | $189.31M | - | - | - | - | - |
| Total Liabilities | $380.99M | $378.69M | $292.15M | $278.23M | $272.23M | - | - | - | - | - |
| Stockholders' Equity | $530.72M | $537.85M | $537.75M | $461.03M | $466.20M | - | - | $175.13M | $0 | $171.02M |
| Retained Earnings | ($44.31M) | ($34.42M) | ($33.27M) | ($33.68M) | ($23.29M) | - | - | - | - | - |
Cash Flow
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q3 '19 | Q2 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($12.63M) | - | - | - | - | - | - | - | - |
| Investing Cash Flow | - | ($4.35M) | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | $75.28M | - | - | - | - | - | - | - | - |
| CapEx | - | $3.06M | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | ($15.69M) | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q3 '19 | Q2 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -9.3% | 3.6% | - | 3.0% | -4.7% | - | - | - | - | - |
| EBITDA margin | 0.7% | 11.3% | - | 11.4% | 6.5% | - | - | - | - | - |
| Net margin | -11.0% | -1.2% | - | 4.5% | -21.3% | - | - | - | - | - |
| Free cash flow margin | - | -16.2% | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 13.60 | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 26.8% | 24.0% | - | 25.8% | 48.1% | - | - | - | - | - |
| Effective tax rate | - | - | - | 23.5% | - | - | - | - | - | - |
| Return on assets | -1.1% | -0.1% | - | 0.5% | -1.6% | - | - | - | - | - |
| Return on equity | -1.9% | -0.2% | - | 0.8% | -2.8% | - | - | - | - | - |
| Return on invested capital | -0.8% | 0.3% | - | 0.3% | -0.4% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.20 | 2.45 | 1.88 | 1.92 | 0.99 | - | - | - | - | - |
| Quick ratio | 1.60 | 1.81 | 1.68 | 1.69 | 0.87 | - | - | - | - | - |
| Cash ratio | 0.31 | 0.36 | 0.55 | 0.70 | 0.30 | - | - | - | - | - |
| Leverage | ||||||||||
| Debt / Equity | 0.50 | 0.49 | 0.35 | 0.41 | 0.41 | - | - | - | - | - |
| Debt / Assets | 0.29 | 0.29 | 0.23 | 0.23 | 0.22 | - | - | - | - | - |
| Debt / EBITDA | 422.00 | 24.27 | - | 20.24 | 46.95 | - | - | - | - | - |
| Interest coverage | -2.0x | 0.9x | - | 0.5x | -0.5x | - | - | - | - | - |
| Equity multiplier | 1.72 | 1.70 | 1.54 | 1.77 | 1.81 | - | - | - | - | - |
| Liabilities / Assets | 0.42 | 0.41 | 0.35 | 0.34 | 0.32 | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | 0.11 | - | 0.10 | 0.07 | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 291d | 274d | - | 207d | 264d | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 45.8% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -187.4% | - | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | 24.8% | - | - | - | - | - | - | - | - | - |
| EPS growth (YoY) | 33.3% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 13.8% | - | - | - | - | - | - | - | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$337.60M totalTechnology Enabled Solutions$284.62M · 84.3%
Advisory Services$52.98M · 15.7%
Product / service
$462.19M totalService$177.57M · 38.4%
Product$160.02M · 34.6%
Health Care$93.15M · 20.2%
Technology Service$13.77M · 3.0%
Data Analytics$11.66M · 2.5%
Consulting$6.02M · 1.3%
Peer comparison
Same SIC group: Services-Misc Health & Allied Services, NEC
Comparing Convey Health Solutions Holdings against the 5 most active filers in the same SIC group.